Stock listing
AARD Stock Price, News, Filings & Events — Aardvark Therapeutics, Inc.
Selected listing: AARD · NASDAQ · USD · US
This page tracks Aardvark Therapeutics, Inc.'s AARD:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AARD:NASDAQ. AARD:NASDAQ is the stock-level entry point for investors researching Aardvark Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Aardvark Therapeutics, Inc. (ticker: AARD) is a public company based in the United States with a market capitalization of approximately $128.24 million. The company is focused on developing innovative therapeutic solutions. Aardvark Therapeutics aims to address unmet medical needs through its research and development efforts.

- Ticker
- AARD:NASDAQ
- Asset type
- Stock
- Market cap
- $112.3M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Aardvark Therapeutics, Inc. AARD:NASDAQ stock context
This page tracks Aardvark Therapeutics, Inc.'s AARD:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AARD:NASDAQ. AARD:NASDAQ is the stock-level entry point for investors researching Aardvark Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Aardvark Therapeutics, Inc. (ticker: AARD) is a public company based in the United States with a market capitalization of approximately $128.24 million. The company is focused on developing innovative therapeutic solutions. Aardvark Therapeutics aims to address unmet medical needs through its research and development efforts.
Latest news from Aardvark Therapeutics, Inc.
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 11, 2026
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 14, 2026
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
February 27, 2026
Research Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for AARD:NASDAQ.
Aardvark Therapeutics, Inc. company profile
View the public company page for Aardvark Therapeutics, Inc. on 6ix.
Aardvark Therapeutics, Inc. news
Read company news and market updates connected to Aardvark Therapeutics, Inc..
Aardvark Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Aardvark Therapeutics, Inc..